Marta Pinto

Ms. Marta Pinto

CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Lisboa, Portugal
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2023 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
BFBeatriz Fernandes
Beatriz Fernandes
Susana AlvesSusana Alves
Susana Alves
VSVanessa Schmidt
Vanessa Schmidt
ABAna Filipa Bizarro
Ana Filipa Bizarro
MPMarta Pinto
Marta Pinto
ALAna Mafalda Lourenço
Ana Mafalda Lourenço
Canine atopic dermatitis (cAD) is a common and distressing skin condition in dogs, affecting up to 30% of the canine population. It not only impacts their quality of life but also that of their owners. Like human atopic dermatitis (hAD), cAD has a complex pathogenesis, including genetic and environmental factors. Current treatments focus on managing clinical signs, but they can be costly and have limitations. This article emphasizes the importance of preventing cAD from developing in the first place. Understanding the role of the skin’s protective barrier is crucial, as its dysfunction plays a vital role in both hAD and cAD. hAD prevention studies have shown promising results in enhancing the skin barrier, but more research is needed to support more robust conclusions. While hAD primary prevention is currently a focal point of intensive investigation in human medicine, research on cAD primary prevention remains under-researched and almost non-existent. Pioneering effective prevention strategies for cAD holds immense potential to enhance the quality of life for both dogs and their owners. Additionally, it bears the promise of a translational impact on human research. Hence, further exploration of this crucial topic is not only relevant but also timely and imperative, warranting support and encouragement.

11 March 2022 in Revista Portuguesa de Imunoalergologia
Verified
Journal Article
Closed access
MPMarta Pinto
Marta Pinto
MSMaria Silva
Maria Silva
BFBeatriz Fernandes
Beatriz Fernandes
ABAna Filipa Bizarro
Ana Filipa Bizarro
HPHugo Pereira
Hugo Pereira
ALAna Lourenço
Ana Lourenço
Background and objective: Lokivetmab is the first anti-canine interleukin-31 monoclonal antibody approved in the European Union for Canine Atopic Dermatitis (CAD) management. This study aimed to assess the lokivetmab’s efficacy and safety in treating CAD cases from a university reference service, as well as the dog’s owner’s overall opinion regarding therapy. Methods: Eighteen atopic dogs were enrolled to perform two subcutaneous injections of lokivetmab, according to the protocol. In order to determine the efficacy and safety of the treatment, skin lesions, pruritus score, blood count, liver parameters and adverse side effects were evaluated over 56 days. The overall pet owner’s satisfaction about the therapy was assessed at the end of the study, and the number of animals that maintained the treatment three months after the end of the study was considered. Results: There was a significant reduction in pruritus score over the eight weeks, with 76.5% of the dogs showing a significant clinical improvement. Regarding the lesion score, 77.8% of the dogs achieved significant clinical improvement, with 61.1% reaching it in the first 4 weeks. There were no reported adverse side effects or changes in blood tests. Pet owner’s opinion regarding the improvement of both the dog and its family’s quality of life was very positive, and three months after the end of the study, 77.8% of the dogs continued their therapy with lokivetmab. Conclusion: Lokivetmab proved to be extremely effective and safe, in addition to sparing pet owners from at home drug administrations, which also contributes to their high satisfaction degree. The great specificity of this biological therapy makes it one of the most potent and promising in the CAD field.

12 February 2025 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
ABAna Filipa Bizarro
Ana Filipa Bizarro
VSVanessa Merta Schmidt
Vanessa Merta Schmidt
BFBeatriz Fernandes
Beatriz Fernandes
MPMarta Pinto
Marta Pinto
HPHugo Pereira
Hugo Pereira
ALAna Mafalda Lourenço
Ana Mafalda Lourenço
Atopic dermatitis is prevalent in humans (hAD) and dogs (cAD) and profoundly impacts the patients’ quality of life. The increasing number of new drugs in development for atopic dermatitis indicates both the need and potential for precision medicine to generate an optimised benefit–risk therapeutic plan. Cannabidiol (CBD), known for its potential anti-inflammatory and antipruritic properties, shows promise in hAD and cAD management, prompting the exploration of cannabinoids (CBs) and CBD as therapeutic tools. In fact, encouraging results on the benefits of using CBD in cAD have been published, along with safety evaluations that reveal that CBD is generally well tolerated in dogs. However, limited placebo-controlled trials and dosage variations in dogs pose barriers that hinder definitive conclusions. Challenges in product stability, inconsistent formulations, and legal ambiguities highlight the need for standardised CBD-based products for both research and commercial uses. The complex legal landscape further complicates accessibility and regulation. Despite these challenges, CBD is emerging as a potential avenue for cAD management, urging further high-quality research, standardised formulations, and legal clarity. This brief review provides valuable insights into the therapeutic potential of CBs and CBD in cAD, compared to hAD, emphasising the importance of rigorous research and unambiguous regulation for successful integration into veterinary dermatology.

11 March 2022 in Revista Portuguesa de Imunoalergologia
Verified
Journal Article
Open access
ABAna Filipa Bizarro
Ana Filipa Bizarro
AMAnabela Martins
Anabela Martins
MPMarta Pinto
Marta Pinto
BFBeatriz Fernandes
Beatriz Fernandes
HPHugo Pereira
Hugo Pereira
ALAna Lourenço
Ana Lourenço
Introdução: O oclacitinib é um inibidor seletivo da enzima cinase de Janus, que tem como alvo a interleucina-31, sendo utilizado no tratamento da dermatite atópica canina. Apesar de os tutores apresentarem um elevado grau de satisfação com este fármaco, o seu custo representa um foco de preocupação para 75%, sendo que 42,5% dos tutores referiram ter de limitar outras despesas para poderem pagar o tratamento do seu cão. Objetivos: Avaliar a possibilidade de adotar um protocolo alternativo com oclacitinib em dias alternados. Secundariamente, avaliar se existe vantagem em adicionar glucocorticoides orais no início deste protocolo. Métodos: Estudo prospetivo, aleatório, duplamente cego e controlado com placebo, incluindo 16 cães com diagnóstico de dermatite atópica, alocados nos grupos P (n=7; Placebo) e G (n=9; Glucocorticoides). Os animais foram avaliados quanto à gravidade lesional (CADESI-04) e grau de prurido (PVAS) no Dia -30, Dia 0 e end-point (recidiva ou Dia 30). O estudo comportou duas fases distintas e sucessivas. Na primeira fase foi administrado oclacitinib (0,4-0,6 mg/kg, 14 dias, duas vezes por dia [BID], depois 16 dias, uma vez por dia [SID]) por via oral a ambos os grupos. No entanto, nos primeiros 7 dias, ao grupo G foi administrada prednisolona (1mg/kg SID) por via oral e ao grupo P um placebo no mesmo regime. Na segunda fase, todos os animais realizaram o mesmo tratamento, mantendo o oclacitinib, mas apenas em dias alternados, até à recidiva do seu quadro clínico. Resultados: Foi possível adotar o protocolo em dias alternados durante pelo menos 30 dias em 71,43% dos animais. As diferenças encontradas não foram estatisticamente significativas entre as médias de CADESI-04 e grau de prurido dos dois grupos no Dia 0 e no end-point. Também não foram encontradas diferenças entre os períodos de tempo médios sob o tratamento em dias alternados. Conclusões: Existe potencial neste protocolo em dias alternados que permite reduzir os custos mensais para metade, possibilitando um maior acesso a esta ferramenta terapêutica inovadora, segura e muito eficaz, mas também dispendiosa. Não parece existir benefício, em termos de redução da dose de oclacitinib, na introdução de prednisolona no início do tratamento.

20 November 2023 in Allergy
Verified
Journal Article
Closed access
MPMarta Pinto
Marta Pinto
Solange GilSolange Gil
Solange Gil
LRLaura Ramió‐Lluch
Laura Ramió‐Lluch
VSVanessa Merta Schmidt
Vanessa Merta Schmidt
HPHugo Miguel Lino Pereira
Hugo Miguel Lino Pereira
ALAna Mafalda Gonçalves Xavier Félix Lourenço
Ana Mafalda Gonçalves Xavier Félix Lourenço

25 August 2023 in Veterinary Dermatology
Verified
Journal Article
Closed access
BFBeatriz Fernandes
Beatriz Fernandes
Afonso CavacoAfonso Cavaco
Afonso Cavaco
MPMarta Pinto
Marta Pinto
ABAna Filipa Bizarro
Ana Filipa Bizarro
HPHugo Pereira
Hugo Pereira
ALAna Mafalda Lourenço
Ana Mafalda Lourenço